Potential protection until 2050.

NFL-101 is derived from a standardized blend of tobacco leaf proteins, and has given rise to three patent families.

The first, filed in 2006, covers the use of tobacco leaf extracts in the treatment of tobacco dependence, and provides protection until 2034 (with extension). Patents have been granted in many countries, including the United States, the major European countries, Russia, Japan, South Korea and India.

The second, filed in 2016, covers the use of specific constituents of tobacco leaves for the treatment of tobacco dependence until 2041 (with extension). Patents have also been granted in many countries, including the United States, Europe, Russia, China, Japan, South Korea and India.

The third, filed in 2022 in the United States, covers the use of NFL-101 as a pre-treatment before a quit attempt, and in combination with nicotine substitutes or other smoking cessation medications. A broad international extension is planned.